AG
NGM

Aperio Group’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Aperio Group’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$319K Buy
+10,526
New +$230K ﹤0.01% 2161
2020
Q2 		– Sell
-10,639
Closed -$131K – 2399
2020
Q1 		$131K Buy
+10,639
New +$174K ﹤0.01% 2177

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GA
Greenspring Associates Owings Mills, Maryland $1.48B AUM 61.93% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Aperio Group's NGM Position: Q4 2020 in Review

Aperio Group opened a new position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2020: 10,526 shares worth $319K. The stake represents ﹤0.01% of the portfolio and ranks #2161 among its holdings. This is a return to the name: Aperio Group previously reported a position in NGM as recently as Q1 2020.

Aperio Group first reported a position in NGM in Q1 2020 and has held it in 2 quarters since. 88 funds tracked by Wall St. Rank hold NGM as of Q4 2020.

  • Aperio Group held 10,526 shares of NGM Biopharmaceuticals, Inc. Common Stock worth $319K as of Q4 2020.
  • NGM Biopharmaceuticals, Inc. Common Stock was a new Aperio Group position in Q4 2020.
  • NGM Biopharmaceuticals, Inc. Common Stock made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2161 holding.
  • Aperio Group first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2020 and has held it in 2 quarters since.
  • 88 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.